Nebivolol is a third-generation, highly beta-1 selective adrenergic receptor blocker that is distinguished by its ability to promote endothelial nitric-oxide release, producing peripheral vasodilation in addition to standard beta-blockade. It is used primarily to treat hypertension, either alone or in combination with other antihypertensive agents. Its vasodilatory profile tends to produce a more favorable metabolic and hemodynamic effect than older beta-blockers.

Nebivolol

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Read the sources → Compare profiles

Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Nebivolol is a third-generation, highly beta-1 selective adrenergic receptor blocker that is distinguished by its ability to promote endothelial nitric-oxide release, producing peripheral vasodilation in addition to standard beta-blockade. NutriStack rates the supporting evidence as strong. Common adult dosing is Typical adult starting dose is 5 mg once daily; may be titrated at 2-week intervals up to 40 mg once daily based on blood pressure response. Lower starting doses (2.5 mg) are advised in patients with hepatic impairment or severe renal impairment., though a prescriber sets the actual dose. With long-term use it can deplete coenzyme q10. This profile indexes 2 sources.

What it's good for

Treatment of hypertension¹
Reduction of systemic vascular resistance via nitric-oxide-mediated vasodilation¹
Lowering of blood pressure with a relatively favorable metabolic profile¹

What to watch for

Headache
Fatigue
Dizziness
Severe bradycardia
Second- or third-degree heart block (without a functioning pacemaker)

The bottom line

Evidence rating strong. Most-documented uses: treatment of hypertension, reduction of systemic vascular resistance via nitric-oxide-mediated vasodilation, lowering of blood pressure with a relatively favorable metabolic profile. 2 sources indexed (1977–2021), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Nebivolol selectively antagonizes beta-1 adrenergic receptors, reducing heart rate, myocardial contractility, and cardiac output, and decreasing renin release from the kidney. At clinically relevant doses in extensive metabolizers it preserves high beta-1 selectivity, sparing beta-2 receptors and limiting bronchospasm and adverse metabolic effects. A defining feature is its modulation of the L-arginine/nitric-oxide pathway, stimulating endothelial nitric-oxide synthase to release nitric oxide, which causes vasodilation and lowers systemic vascular resistance. As a class effect, chronic beta-blockade can reduce endogenous coenzyme Q10 (ubiquinone) levels, partly by interfering with mitochondrial and CoQ10-dependent enzyme activity.^1,2

Class

Beta-blocker (beta-1 selective with vasodilation)

Dosing

Dosing & protocol.

Common range

Typical adult starting dose is 5 mg once daily; may be titrated at 2-week intervals up to 40 mg once daily based on blood pressure response. Lower starting doses (2.5 mg) are advised in patients with hepatic impairment or severe renal impairment.

Recommended form

Oral tablet

Can be taken with or without food; absorption is not meaningfully affected by meals. Metabolism is heavily dependent on CYP2D6, so plasma levels are substantially higher in poor metabolizers.

Depletions

What it depletes.

Nutrients this medication can lower over time, and what to replace.

Coenzyme Q10

Mild

Beta-adrenergic blockers, including nebivolol, are recognized as a class to lower circulating coenzyme Q10 (ubiquinone). The proposed mechanism is inhibition of CoQ10-dependent enzymatic reactions and interference with CoQ10 biosynthesis or mitochondrial bioenergetic pathways, since CoQ10 and beta-blockers share structural similarity and CoQ10 participates in the same electron-transport processes the drugs can perturb. The reduction in myocardial and plasma CoQ10 has been hypothesized to contribute to some beta-blocker adverse effects.

Replace Coenzyme Q10 (ubiquinone or ubiquinol)Monitor Plasma/serum coenzyme Q10 concentration (not routinely measured clinically)Onset Weeks to months of continued therapy

Full Nebivolol depletion and interaction guide →

Safety

Full safety detail.

Side effects

Headache
Fatigue
Dizziness
Bradycardia
Hypotension
Diarrhea or nausea
Peripheral edema
Cold extremities

Contraindications

Severe bradycardia
Second- or third-degree heart block (without a functioning pacemaker)
Sick sinus syndrome
Cardiogenic shock
Decompensated heart failure
Severe hepatic impairment
Known hypersensitivity to nebivolol¹

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Reference material

1Nebivolol (Bystolic) Prescribing InformationAllergan / AbbVie · FDA Prescribing Information · 2021
Nebivolol lowers blood pressure through beta-1 blockade and endothelial nitric-oxide-dependent vasodilation; dosing 5-40 mg once daily.
2Influence of beta-blockers on coenzyme Q10 statusKishi T, et al. · Journal of Medicine · 1977
Several beta-adrenergic blocking agents inhibit CoQ10-dependent mitochondrial enzymes, supporting a class effect of CoQ10 depletion.

FAQ

Common questions.

Quick answers about Nebivolol, drawn from the data on this page.

What is Nebivolol?

What is Nebivolol used for?

Commonly cited benefits of Nebivolol include: Treatment of hypertension; Reduction of systemic vascular resistance via nitric-oxide-mediated vasodilation; Lowering of blood pressure with a relatively favorable metabolic profile. NutriStack rates the overall evidence as strong.

What is a typical dose of Nebivolol?

A typical adult dose of Nebivolol is Typical adult starting dose is 5 mg once daily; may be titrated at 2-week intervals up to 40 mg once daily based on blood pressure response. Lower starting doses (2.5 mg) are advised in patients with hepatic impairment or severe renal impairment.. The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Nebivolol?

Reported side effects include headache, fatigue, dizziness, bradycardia, hypotension, diarrhea or nausea. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Nebivolol?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Nebivolol in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology